166 related articles for article (PubMed ID: 15790436)
1. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
4. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.
Haitel A; Wiener HG; Baethge U; Marberger M; Susani M
Clin Cancer Res; 2000 May; 6(5):1840-4. PubMed ID: 10815906
[TBL] [Abstract][Full Text] [Related]
5. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
6. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
7. p53 and related proteins in epithelial ovarian cancer.
Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
[TBL] [Abstract][Full Text] [Related]
8. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
9. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities.
Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H
Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860
[TBL] [Abstract][Full Text] [Related]
10. Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteins.
Tachibana M; Watanabe J; Matsushima Y; Nishida K; Kobayashi Y; Fujimura M; Shiromizu K
Int J Gynecol Cancer; 2003; 13(5):598-606. PubMed ID: 14675342
[TBL] [Abstract][Full Text] [Related]
11. Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer.
Baekelandt M; Holm R; Nesland JM; Tropé CG; Kristensen GB
J Clin Oncol; 2000 Nov; 18(22):3775-81. PubMed ID: 11078490
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of KAI1 metastasis suppressor protein is associated with a dismal prognosis in epithelial ovarian cancer.
Schindl M; Birner P; Breitenecker G; Oberhuber G
Gynecol Oncol; 2001 Nov; 83(2):244-8. PubMed ID: 11606078
[TBL] [Abstract][Full Text] [Related]
14. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation.
Saito H; Tsujitani S; Oka S; Ikeguchi M; Maeta M; Kaibara N
Ann Surg Oncol; 2002 Jun; 9(5):450-6. PubMed ID: 12052755
[TBL] [Abstract][Full Text] [Related]
15. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
Tuna B; Yörükoğlu K; Tüzel E; Güray M; Mungan U; Kirkali Z
Pathol Res Pract; 2003; 199(5):323-8. PubMed ID: 12908522
[TBL] [Abstract][Full Text] [Related]
17. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ
Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
[TBL] [Abstract][Full Text] [Related]
18. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
19. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]